PacBio Enters Material Definitive Agreement, Reports Equity Sales

Ticker: PACB · Form: 8-K · Filed: 2024-11-07T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-obligation, equity-sale

Related Tickers: PACB

TL;DR

PacBio signed a big deal and sold some stock, details to come.

AI Summary

On November 7, 2024, Pacific Biosciences of California, Inc. (PacBio) entered into a material definitive agreement related to a direct financial obligation. The company also reported on unregistered sales of equity securities and other events. Specific details regarding the agreement and financial obligations were not fully disclosed in this initial filing.

Why It Matters

This filing indicates significant financial and corporate actions by PacBio, potentially impacting its financial obligations and shareholder structure.

Risk Assessment

Risk Level: medium — The filing mentions material definitive agreements and financial obligations, which could carry inherent risks depending on the specifics not yet fully detailed.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by PacBio?

The filing states that PacBio entered into a material definitive agreement, but the specific terms and nature of this agreement are not detailed in this initial 8-K filing.

What type of direct financial obligation is PacBio reporting?

The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specifics of this obligation are not provided.

What were the circumstances of the unregistered sales of equity securities?

The filing notes unregistered sales of equity securities, but does not provide details on the number of shares, price, or the purchasers involved.

Are there any other significant events reported in this filing besides the agreement and equity sales?

Yes, the filing also lists 'Other Events' and 'Financial Statements and Exhibits' as items being reported, though specific details for these are not elaborated in the provided text.

When was this Form 8-K filed and what period does it cover?

This Form 8-K was filed on November 7, 2024, and it reports on events occurring as of the same date, November 7, 2024.

From the Filing

0001104659-24-115291.txt : 20241107 0001104659-24-115291.hdr.sgml : 20241107 20241107160313 ACCESSION NUMBER: 0001104659-24-115291 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241107 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241107 DATE AS OF CHANGE: 20241107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 241435437 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 tm2427787d2_8k.htm FORM 8-K false 0001299130 0001299130 2024-11-07 2024-11-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549    FORM 8-K    CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) November 7, 2024    Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter)    Delaware   001-34899   16-1590339 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code)   ( 650 ) 521-8000 (Registrant’s telephone number, including area code)     (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   PACB   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 1.01 Entry into a Material Definitive Agreement.   Letter Agr

View on Read The Filing